Industry Perspective: Expanded Access Programs - ppt download
Report of an international expanded access program of imatinib in adults with Philadelphia chromosome positive leukemias - Annals of Oncology
WideTrial
PDF) Real-world data from expanded access programmes in health technology assessments: a review of NICE technology appraisals
The Regulatory Debate Around Pre-approval Product Access
PDF) Expanded Access Programme: Looking for a common definition
TEAMSS (Transforming Expanded Access to Maximize Support and Study) | clic
Pooled allogenic fecal microbiotherapy MaaT013 for the treatment of steroid-refractory gastrointestinal acute graft-versus-host disease: results from the phase IIa HERACLES study and expanded access program - MaaT Pharma
Right to Try fails to show 'edge' vs. Expanded Access pathway among community oncologists
Investigational Drugs and Biologics | Research
Virtual Clinical Trials Market Size, Share & Trends Analysis Report by Study Design (Interventional, Observational, Expanded Access), by Indication (Oncology, Cardiovascular), by Region, and Segment Forecasts, 2022-2030
Industry Perspective: Expanded Access Programs - ppt download
Expanded Access | Information for Patients | FDA
Analysis of Patients Completing the Ibalizumab Phase 3 Trial and Expanded Access Program
Single Patient Access to Investigational Therapeutic Agents Resource Guide
Navigating Expanded Access
Expanded Access Programs, compassionate drug use, and Emergency Use Authorizations during the COVID-19 pandemic. - ScienceDirect
Clinical Trials Market Size, Growth, Trends, Report 2023-2030
Access to and safety of COVID-19 convalescent plasma in the United States Expanded Access Program: A national registry study | PLOS Medicine
Regulatory Explainer: FDA's Expanded Access (Compassionate Use) Program | RAPS
Expanded access to investigational drugs: balancing patient safety with potential therapeutic benefits
Expanded Access to Investigational Drugs - IRB - The University of Utah
Expanded Access vs. Right to Try: What Patients Need to Know » Triage Cancer | Finances-Work-Insurance
How to complete an Expanded Access Drug or Device Application
Navigating Expanded Access
Study Design of an Expanded Access Protocol of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection in Patients 60-75 Years of Age with Secondary Acute Myeloid Leukemia - Biology of Blood and Marrow Transplantation
